Advertisement
![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
Organisation › Details
Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF)
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100™ (aviptadil), synthetic vasoactive intestinal peptide (VIP), is being investigated in two placebo-controlled U.S. Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100™ is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100™ under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of RLF-100™ to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100™. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. *
![]() |
Start | 2016-06-01 merged |
Group | Relief Therapeutics (Group) | |
![]() |
Industry | pharmaceutical active protein |
Industry 2 | aviptadil (NN) | |
![]() |
Person | Selvaraju, Raghuram (Ram) (Relief Therapeutics 202010 Board Chairman) |
Person 2 | Weinstein, Jack (Relief Therapeutics 202010– CFO before Avalon Group + Catalyst Pharmaceuticals + Sterlington Group) | |
![]() |
Region | Genève (Geneva) GE |
Country | Switzerland | |
Street | 15 Avenue de Sécheron Fondation EIP, Bâtiment F2/F3 | |
City | 1202 Genève GE | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: Relief Therapeutics Holding AG. (10/8/20). "Press Release: Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer". Geneva. | ||
Record changed: 2020-10-09 |
Advertisement

More documents for Relief Therapeutics (Group)
- [1] Relief Therapeutics Holding AG. (10/8/20). "Press Release: Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer". Geneva....
- [2] PX’Therapeutics S.A.. (10/5/16). "Press Release: PX’Therapeutics and Relief Therapeutics Holding AG Announce a Strategic Collaboration Agreement for the Recombinant Production of Atexakin Alfa". Grenoble & Geneva....
- [3] Therametrics Holding AG. (9/3/13). "Press Release: Therametrics Holding AG (SIX: TMX) Today Announces the Resignation of Mr. Ruggero Gramatica as CEO and Director as of the End of September 2013 and the Appointment of Mr. Raffaele Petrone as New CEO with...
- [4] Mondobiotech Holding AG. (5/3/12). "Press Release: Mondobiotech Holding AG (SIX: RARE) Announces the Results of Its Annual General Meeting and Re-elections in the Board of Directors". Stans....
- [5] Mondobiotech Holding AG. (5/2/12). "Press Release: Mondobiotech Holding AG Announces Changes in the Composition of the Board of Directors". Stans....
- [6] Mondobiotech Holding AG. (4/20/12). "Press Release: Mondobiotech and Pierrel Agree to Stop Negotiations for a Business Combination". Milan & Stans....
- [7] Mondobiotech Holding AG. (3/1/12). "Press Release: Pierrel SpA and Mondobiotech Holding AG Announce Today that They Have Entered into Exclusive Negotiations, with Regard to a Potential Business Combination". Milano & Stans....
- [8] Mondobiotech Holding AG. (11/25/11). "Press Release: MondoBiotech Holding AG (SIX: RARE) Sets Out to Clarify Some Statements Appearing in Today’s Press". Stans....
- [9] Mondobiotech Holding AG. (11/24/11). "Press Release: MondoBiotech Holding AG (SIX: RARE) Announces Restructuring Measures Aimed at Preserving the Value of Its Core Assets". Stans....
- [10] Mondobiotech Holding AG. (11/14/11). "Press Release: MondoBiotech Holding AG (SIX: RARE) Announces the Execution of a Loan Facilty Granted by the Company’s Largest Shareholder". Stans....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top